

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported)**  
May 4, 2026

---

**Twist Bioscience Corporation**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-38720**  
(Commission  
File Number)

**46-2058888**  
(I. R. S. Employer  
Identification No.)

**681 Gateway Boulevard**  
**South San Francisco, CA 94080**  
(Address of principal executive offices, including ZIP code)

**(800) 719-0671**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TWST	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---



**Item 2.02 Results of Operations and Financial Condition.**

On May 4, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press release dated May 4, 2026 titled “Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results”</a>
104	Cover Page Interactive Data File (formatted as Inline XBRL)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 4, 2026

**Twist Bioscience Corporation**

/s/ Judy Yan

Judy Yan

Assistant General Counsel and Assistant Secretary



## Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results

— Record revenue of \$110.7 million in 2QFY26; Increase of more than 19% over \$92.8 million in 2QFY25; 13th consecutive quarter of sequential growth —

— Gross margin of 51.6% in 2QFY26; Improvement of approximately 2 margin points versus 2QFY25 —

— Revenue guidance raised to \$442-\$447M; Reiterating Q4 FY26 Adj EBITDA breakeven —

**SOUTH SAN FRANCISCO, Calif.** -- (May 4, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today reported financial results and business highlights for the second quarter ended March 31, 2026.

"We had a strong performance in the first half of fiscal 2026, ending the second quarter with our thirteenth consecutive quarter of growth. Revenue exceeded guidance, coming in at \$110.7 million, growth of over 19% compared to the second quarter of 2025," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "As we look ahead, we remain focused on delivering consistent, measurable growth designed to scale over time. We expect to chart toward profitability while simultaneously building on the strong momentum we are seeing across the portfolio. We continue to anticipate achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while holding gross margin above 52% for the fiscal year."

See "Non-GAAP Information" below for a discussion of the measure adjusted EBITDA.

### FISCAL 2026 SECOND QUARTER FINANCIAL RESULTS

- **Revenue:** Total revenues for the second quarter of fiscal 2026 grew 19% to \$110.7 million compared to \$92.8 million for the same period of fiscal 2025.
  - DNA Synthesis and Protein Solutions (DSPS) revenue grew 28% to \$53.3 million for the second quarter of fiscal 2026 compared to \$41.6 million for the same period of fiscal 2025, and grew 4% sequentially, compared to \$51.1 million for the first quarter of fiscal 2026.
  - NGS Applications (NGS) revenue grew 12% to \$57.4 million for the second quarter of fiscal 2026 compared to \$51.1 million for the same period of fiscal 2025, and grew 9% sequentially, compared to \$52.6 million for the first quarter of fiscal 2026.
- **Cost of Revenues:** Cost of revenues for the second quarter of fiscal 2026 increased to \$53.6 million compared to \$46.8 million for the same period of fiscal 2025.
- **Gross Margin:** Gross margin for the second quarter of fiscal 2026 increased to 51.6% compared to 49.6% for the same period of fiscal 2025.

- **Research and Development Expenses:** Research and development expenses for the second quarter of fiscal 2026 decreased to \$19.7 million compared to \$23.9 million for the same period of fiscal 2025.
- **Selling, General and Administrative Expenses:** Selling, general and administrative expenses for the second quarter of fiscal 2026 were \$76.1 million compared to \$63.7 million for the same period of fiscal 2025.
- **Litigation Settlement:** We reached a settlement in principle regarding the securities class action for approximately \$17.1 million. \$7.2 million was booked for litigation settlement costs, net of recoveries in the second quarter of fiscal 2026.
- **Net Loss:** Net loss for the second quarter of fiscal 2026 increased to \$44.0 million, or \$0.71 per share, compared to \$39.3 million, or \$0.66 per share, for the same period of fiscal 2025.
- **Adjusted EBITDA:** Adjusted EBITDA for the second quarter of fiscal 2026 was \$(13.3) million compared to \$(14.8) million for the same period of fiscal 2025. See the table included in this release for a reconciliation between adjusted EBITDA, which excludes litigation settlement costs, and net loss attributable to common stockholders, the most directly comparable GAAP financial measure.
- **Cash Position:** As of March 31, 2026, the company had approximately \$172 million in cash, cash equivalents and short-term investments.

#### Recent Highlights:

- Shipped products to approximately 2,583 customers in the second quarter of fiscal 2026, versus approximately 2,431 in the same period of fiscal 2025.
- Physically shipped approximately 300,000 genes in the second quarter of fiscal 2026, compared with approximately 227,000 in the same period of fiscal 2025.
- Entered into bispecific licensing agreement to become the co-exclusive provider, together with Invenra, of Invenra's B-Body® bispecific antibody platform, extending Twist's antibody discovery services.
- Amazon Web Services announced Twist as a wet lab partner for Amazon Bio Discovery, its AI-powered drug discovery application.
- Launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research.

#### Fiscal 2026 Financial Guidance

The following statements are based on Twist's current expectations for fiscal 2026. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below.

For the full fiscal year 2026, Twist expects:

- Total revenue in the range of \$442 million to \$447 million, growth of 17% to 19%, compared to prior guidance of \$435 to \$440 million.
- Gross margin to be above 52% for fiscal 2026

For the third quarter, Twist expects:

- Total revenue of approximately \$114 million to \$115 million, growth of approximately 19% year over year at the midpoint. As previously discussed, we expect NGS to be the driver of sequential growth in H2 and return to 20% growth by 4Q.

For the fourth quarter, Twist expects:

- To achieve adjusted EBITDA breakeven for the fourth quarter of fiscal 2026

### **Non-GAAP Information**

This release includes EBITDA and adjusted EBITDA, which are non-GAAP financial measures, for the periods presented. EBITDA is defined as net loss adjusted to exclude interest income, income tax expense and depreciation and amortization. Adjusted EBITDA is defined as net loss adjusted to exclude interest income, income tax expense, depreciation and amortization, litigation settlement costs, net of recoveries, other income/expense, net, and stock-based compensation expense. These non-GAAP measures are not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. We believe that these non-GAAP financial measures, when considered together with our financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. However, non-GAAP information is not superior to financial measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. A reconciliation table of the most comparable GAAP financial measure to the non-GAAP financial measures is included at the end of this press release.

A reconciliation of adjusted EBITDA for the fourth quarter of fiscal 2026 to a corresponding GAAP financial guidance measure is not available on a forward-looking basis because the Company does not provide guidance on GAAP net loss and is not able to present the various reconciling cash and non-cash items between GAAP net loss and adjusted EBITDA without unreasonable effort. In particular, stock-based compensation expense is impacted by the Company's future hiring and retention needs, as well as the future fair market value of its

common stock, all of which is difficult to predict and is subject to change. The actual amount of these expenses during the fourth quarter of fiscal 2026 will have a significant impact on Twist's future GAAP financial results.

### **Conference Call Information**

The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company's business. The conference call will be webcast live through the Investor Relations section under the "Company" tab at [www.twistbioscience.com](http://www.twistbioscience.com). Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking [here](#). Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

### **About Twist Bioscience**

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.

We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.

Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit [www.twistbioscience.com](http://www.twistbioscience.com).

Follow us on [LinkedIn](#) | [X](#) | [YouTube](#) | [Instagram](#) | [Bluesky](#)

### **Legal Notice Regarding Forward-Looking Statements**

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading "Fiscal 2026 Financial Guidance," statements regarding future growth and expansion, drivers of future revenue and gross margin growth, estimated annual revenues, ability and

timing to achieve profitability, ability and timing to achieve adjusted EBITDA breakeven and ability to maintain or increase gross margins and Twist's other expectations regarding its future operations plans and financial performance, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; risks associated with the spin out of Atlas Data Storage; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 17, 2025. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

**For Investors:**

Angela Bitting  
SVP, Corporate Affairs  
925-202-6211  
[abitting@twistbioscience.com](mailto:abitting@twistbioscience.com)

**For Media:**

Amanda Houlihan  
Communications Manager  
774-265-5334  
[ahoulihan@twistbioscience.com](mailto:ahoulihan@twistbioscience.com)

**Twist Bioscience Corporation**  
**Condensed Consolidated Statements of Operations**  
**(Unaudited)**  
**(in thousands)**

(In thousands, except per share data)	Three months ended March 31,		Six months ended March 31,	
	2026	2025	2026	2025
Revenues	\$ 110,715	\$ 92,793	\$ 214,413	\$ 181,506
Costs and expenses:				
Cost of revenues	\$ 53,593	\$ 46,765	\$ 103,319	\$ 92,638
Research and development expenses	19,695	23,917	36,825	45,224
Selling, general and administrative expenses	76,085	63,671	145,827	119,849
Litigation settlement costs, net of recoveries	7,205	—	7,205	—
Total costs and expenses	\$ 156,578	\$ 134,353	\$ 293,176	\$ 257,711
Loss from operations	\$ (45,863)	\$ (41,560)	\$ (78,763)	\$ (76,205)
Interest income	\$ 1,710	\$ 2,801	\$ 3,885	\$ 6,041
Other income (expense), net	175	(394)	646	(487)
Income tax expense	(43)	(175)	(296)	(271)
Net loss	\$ (44,021)	\$ (39,328)	\$ (74,528)	\$ (70,922)
Net loss per share — basic and diluted	\$ (0.71)	\$ (0.66)	\$ (1.21)	\$ (1.19)
Weighted average shares used in computing net loss per share — basic and diluted	61,702	59,649	61,387	59,403

**Twist Bioscience Corporation**  
**Condensed Consolidated Balance Sheets**  
**(Unaudited)**  
**(in thousands)**

(In thousands)	March 31, 2026	September 30, 2025
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 122,670	\$ 183,049
Short-term investments	49,001	49,385
Accounts receivable, net	64,153	57,019
Inventories	33,515	28,309
Prepaid expenses and other current assets	54,100	15,204
Total current assets	\$ 323,439	\$ 332,966
Property and equipment, net	111,226	102,283
Operating lease right-of-use assets	70,655	49,377
Investment in equity securities	68,087	54,337
Other non-current assets	102,807	102,898
Total assets	\$ 676,214	\$ 641,861
<b>Liabilities and stockholders' equity</b>		
Current liabilities:		
Accounts payable	\$ 14,682	\$ 11,094
Accrued compensation	27,003	31,288
Current portion of operating lease liability	10,443	13,822
Other current liabilities	67,848	35,202
Total current liabilities	\$ 119,976	\$ 91,406
Operating lease liability, net of current portion	85,398	61,750
Liability related to the sale of future revenue	15,000	15,000
Other non-current liabilities	746	747
Total liabilities	\$ 221,120	\$ 168,903
Total stockholders' equity	\$ 455,094	\$ 472,958
Total liabilities and stockholders' equity	\$ 676,214	\$ 641,861

**Twist Bioscience Corporation**  
**Adjusted EBITDA**  
**(Unaudited)**  
**(in thousands)**

The following table sets forth a reconciliation between our Adjusted EBITDA and net loss attributable to Twist Bioscience Corporation, the most directly comparable GAAP financial measure, for each of the periods presented:

(In thousands)	Three months ended March 31,		Six months ended March 31,	
	2026	2025	2026	2025
GAAP net loss	\$ (44,021)	\$ (39,328)	\$ (74,528)	\$ (70,922)
Add (Deduct) adjustments:				
Interest income	\$ (1,710)	\$ (2,801)	\$ (3,885)	\$ (6,041)
Income tax expense	43	175	296	271
Depreciation and amortization	6,414	6,402	12,608	12,784
EBITDA	\$ (39,274)	\$ (35,552)	\$ (65,509)	\$ (63,908)
Add (Deduct) adjustments:				
Litigation settlement costs, net of recoveries	\$ 7,205	\$ —	\$ 7,205	\$ —
Other (income) expense, net	(175)	394	(646)	487
Stock-based compensation expense	18,936	20,328	32,209	32,319
Adjusted EBITDA	\$ (13,308)	\$ (14,830)	\$ (26,741)	\$ (31,102)